Zobrazeno 1 - 10
of 45
pro vyhledávání: '"Matt Coffey"'
Autor:
Kevin Kelly, Matt Coffey, Tomás Pascual, Aleix Prat, Luis Manso, Thomas Heineman, Fernando Salvador, Joaquín Gavilá, Houra Loghmani, Richard Trauger, Akil Merchant, Julian Olea, Homa Dadrastoussi, Eduardo Fernandez Hernandez, Hugo Lara Martinez, Kaijin Wu
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/03ed36044d9b4a3ebd44195b6772b464
Autor:
Nicola E. Annels, Guy R. Simpson, Mick Denyer, Mehreen Arif, Matt Coffey, Alan Melcher, Kevin Harrington, Richard Vile, Hardev Pandha
Publikováno v:
Molecular Therapy: Oncolytics, Vol 20, Iss , Pp 434-446 (2021)
Prostate cancers are considered “cold” tumors characterized by minimal T cell infiltrates, absence of a type I interferon (IFN) signature, and the presence of immunosuppressive cells. This non-inflamed phenotype is likely responsible for the lack
Externí odkaz:
https://doaj.org/article/1fcecfe43cb14392b18d5ef88fd32378
Autor:
Laura Evgin, Amanda L. Huff, Phonphimon Wongthida, Jill Thompson, Tim Kottke, Jason Tonne, Matthew Schuelke, Katayoun Ayasoufi, Christopher B. Driscoll, Kevin G. Shim, Pierce Reynolds, Dileep D. Monie, Aaron J. Johnson, Matt Coffey, Sarah L. Young, Gary Archer, John Sampson, Jose Pulido, Luis Sanchez Perez, Richard Vile
Publikováno v:
Nature Communications, Vol 11, Iss 1, Pp 1-15 (2020)
Oncolytic viruses promote an inflammatory response and elicit anti-tumor immunity. Here the authors show, unexpectedly, that the oncolytic virus, VSVIFNβ, induces type I interferon responses that, when combined with chimeric antigen receptor (CAR) T
Externí odkaz:
https://doaj.org/article/5178c922fdee4c4491424f98809482c4
Autor:
Ruwan Parakrama, Elisha Fogel, Carol Chandy, Titto Augustine, Matt Coffey, Lydia Tesfa, Sanjay Goel, Radhashree Maitra
Publikováno v:
BMC Cancer, Vol 20, Iss 1, Pp 1-11 (2020)
Abstract Background KRAS mutations are prevalent in 40–45% of patients with colorectal cancer (CRC) and targeting this gene has remained elusive. Viruses are well known immune sensitizing agents. The therapeutic efficacy of oncolytic reovirus in co
Externí odkaz:
https://doaj.org/article/88cb56e4959547eb97786d26285e1c57
Autor:
Masaya Igase, Shusaku Shibutani, Yosuke Kurogouchi, Noriyuki Fujiki, Chung Chew Hwang, Matt Coffey, Shunsuke Noguchi, Yuki Nemoto, Takuya Mizuno
Publikováno v:
Molecular Therapy: Oncolytics, Vol 15, Iss , Pp 49-59 (2019)
Oncolytic virotherapy using reovirus is a promising new anti-cancer treatment with potential for use in humans and dogs. Because reovirus monotherapy shows limited efficacy in human and canine cancer patients, the clinical development of a combinatio
Externí odkaz:
https://doaj.org/article/76ffdd340a124cacb754bd898274c7bb
Autor:
Victoria Jennings, Christopher Parrish, Christy Ralph, Alan Melcher, Adel Samson, Gordon Cook, Fiona Errington-Mais, Matt Coffey, Munitta Muthana, Gemma Migneco, Louise M E Müller, Gina B Scott, Jenny Down, Sancha King, Basem Askar, Babatunde Oyajobi, Karen Scott, Emma West, Elizabeth J Ilett, Michelle Lawson
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 3 (2021)
Background Multiple myeloma (MM) remains an incurable disease and oncolytic viruses offer a well-tolerated addition to the therapeutic arsenal. Oncolytic reovirus has progressed to phase I clinical trials and its direct lytic potential has been exten
Externí odkaz:
https://doaj.org/article/db50054d7a414d2980de99757b9e839e
Autor:
Matt Coffey, Aleix Prat, Manel Juan, Luis Manso, Patricia Villagrasa, Nuria Chic, Begoña Bermejo, Juan Cejalvo, Yann Izarzugaza, Blanca Cantos, Salvador Blanch, Mireia Margeli, Jose Alonso, Alejandro Martínez, Rafael Villanueva, Juan Guerra, Raquel Andrés, Pilar Zamora, Esteban Nogales, Blanca Gonzalez-Farre, Thomas Heineman, Gerard Nuovo, Grey Wilkinson, Azucena Gonzalez, Débora Martínez, Laia Paré, Fernando Salvador, Xavier Gonzalez, Joaquín Gavilá
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss Suppl 3 (2020)
Externí odkaz:
https://doaj.org/article/eb8225f17d4d488e949d3a3f2ca4c5d8
Autor:
Guy Ungerechts, Sascha Bossow, Barbara Leuchs, Per S Holm, Jean Rommelaere, Matt Coffey, Rob Coffin, John Bell, Dirk M Nettelbeck
Publikováno v:
Molecular Therapy: Methods & Clinical Development, Vol 3, Iss C (2016)
Oncolytic viruses (OVs) are unique anticancer agents based on their pleotropic modes of action, which include, besides viral tumor cell lysis, activation of antitumor immunity. A panel of diverse viruses, often genetically engineered, has advanced to
Externí odkaz:
https://doaj.org/article/0ae5904ce6684981aeeee2ff23c841d3
Autor:
Chung Chew Hwang, Saori Umeki, Masahito Kubo, Toshiharu Hayashi, Hiroshi Shimoda, Masami Mochizuki, Ken Maeda, Kenji Baba, Hiroko Hiraoka, Matt Coffey, Masaru Okuda, Takuya Mizuno
Publikováno v:
PLoS ONE, Vol 8, Iss 9, p e73555 (2013)
The usage of reovirus has reached phase II and III clinical trials in human cancers. However, this is the first study to report the oncolytic effects of reovirus in veterinary oncology, focusing on canine mast cell tumor (MCT), the most common cutane
Externí odkaz:
https://doaj.org/article/f31d735bb2544fa8b15245950e11dad8
Autor:
Richard G. Vile, Alan Melcher, Kevin J. Harrington, Peter J. Selby, Hardev Pandha, Jose S. Pulido, Matt Coffey, Reuben S. Harris, Karen Kaluza Smith, Elizabeth J. Ilett, Phonphimon Wongthida, Kevin G. Shim, Matthew Schuelke, Christopher B. Driscoll, Amy M. Molan, Jill Thompson, Timothy Kottke, Amanda L. Huff, Laura Evgin
Suppl Fig 3
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2d2df2dac03c88594d6ea75552686923
https://doi.org/10.1158/2326-6066.22537064.v1
https://doi.org/10.1158/2326-6066.22537064.v1